Permanent contraception: Modern approaches justify a new name

Jeffrey T. Jensen

doi:10.1016/j.contraception.2014.01.007

Permanent contraception: Modern approaches justify a new name

Jeffrey T. Jensen

Obstetrics and Gynecology

Research output: Contribution to journal › Comment/debate › peer-review

10 Scopus citations

Original language	English (US)
Pages (from-to)	493-494
Number of pages	2
Journal	Contraception
Volume	89
Issue number	6
DOIs	https://doi.org/10.1016/j.contraception.2014.01.007
State	Published - Jun 2014

ASJC Scopus subject areas

Reproductive Medicine
Obstetrics and Gynecology

Access to Document

10.1016/j.contraception.2014.01.007

Cite this

@article{21e080eeb9dd4aaaa3190c23d781dc75,

title = "Permanent contraception: Modern approaches justify a new name",

author = "Jensen, {Jeffrey T.}",

note = "Funding Information: Financial disclosure: Dr. Jensen has received payments for consulting from Agile Pharmaceuticals, Abbvie Pharmaceuticals, Bayer Healthcare, ContraMed, Evofem Inc, HRA Pharma, Merck Pharmaceuticals, Teva Pharmaceuticals and the Population Council, and for giving talks for Bayer and Merck. He has also received research funding from Abbvie, Bayer, the Population Council, the National Institute of Health and the Bill & Melinda Gates Foundation. These companies and organizations may have a commercial or financial interest in the results of this research and technology. These potential conflicts of interest have been reviewed and managed by OHSU. ",

year = "2014",

month = jun,

doi = "10.1016/j.contraception.2014.01.007",

language = "English (US)",

volume = "89",

pages = "493--494",

journal = "Contraception",

issn = "0010-7824",

publisher = "Elsevier USA",

number = "6",

}

TY - JOUR

T1 - Permanent contraception

T2 - Modern approaches justify a new name

AU - Jensen, Jeffrey T.

N1 - Funding Information: Financial disclosure: Dr. Jensen has received payments for consulting from Agile Pharmaceuticals, Abbvie Pharmaceuticals, Bayer Healthcare, ContraMed, Evofem Inc, HRA Pharma, Merck Pharmaceuticals, Teva Pharmaceuticals and the Population Council, and for giving talks for Bayer and Merck. He has also received research funding from Abbvie, Bayer, the Population Council, the National Institute of Health and the Bill & Melinda Gates Foundation. These companies and organizations may have a commercial or financial interest in the results of this research and technology. These potential conflicts of interest have been reviewed and managed by OHSU.

PY - 2014/6

Y1 - 2014/6

UR - http://www.scopus.com/inward/record.url?scp=84901622952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901622952&partnerID=8YFLogxK

U2 - 10.1016/j.contraception.2014.01.007

DO - 10.1016/j.contraception.2014.01.007

M3 - Comment/debate

C2 - 24560480

AN - SCOPUS:84901622952

SN - 0010-7824

VL - 89

SP - 493

EP - 494

JO - Contraception

JF - Contraception

IS - 6

ER -

Permanent contraception: Modern approaches justify a new name

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this